Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTR Nektar Therapeutics

Pre-Mkt 09-02 09:11:28 EDT

71.75

+0.37

+0.52%

盘前71.70

-0.05-0.07%

08:57 EDT

High72.73	Low70.00	Vol334.11K
Open70.41	D1 Closing71.38	Amplitude3.82%
Mkt Cap2.45B	Tradable Cap2.05B	Total Shares34.14M
T/O24.00M	T/O Rate1.17%	Tradable Shares28.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"Nektar Therapeutics","latestPrice":71.75,"timestamp":1788292800000,"preClose":71.38,"halted":0,"volume":334105,"hourTrading":{"tag":"盘前","latestPrice":71.7,"preClose":71.75,"latestTime":"08:57 EDT","volume":798,"amount":57412.62072,"timestamp":1788353872964,"change":-0.05,"changeRate":-0.000697,"amplitude":0.00463},"delay":0,"changeRate":0.00518352479686193,"floatShares":28534200,"shares":34142994,"eps":-6.468026,"marketStatus":"Pre-Mkt","change":0.37,"latestTime":"09-02 09:11:28 EDT","open":70.41,"high":72.73,"low":70.0001,"amount":24003259.2033,"amplitude":0.038245,"askPrice":72.29,"askSize":38,"bidPrice":70.1,"bidSize":37,"shortable":3,"etf":0,"ttmEps":-6.468026,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788355800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":71.75,"preHourTrading":{"tag":"盘前","latestPrice":71.7,"preClose":71.75,"latestTime":"08:57 EDT","volume":798,"amount":57412.62072,"timestamp":1788353872964,"change":-0.05,"changeRate":-0.000697,"amplitude":0.00463},"postHourTrading":{"tag":"盘后","latestPrice":72.2,"preClose":71.75,"latestTime":"19:30 EDT","volume":45618,"amount":3273263.35,"timestamp":1788305400476,"change":0.45,"changeRate":0.006272,"amplitude":0.006272},"volumeRatio":0.7709879345117256,"impliedVol":0.6916,"impliedVolPercentile":0.2948},"requestUrl":"/m/hq/s/NKTR","defaultTab":"news","newsList":[{"id":"2664002203","title":"Peer‑Reviewed REZOLVE‑AD Phase 2b Data Could Be A Game Changer For Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664002203","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664002203?lang=en_us&edition=fundamental","pubTime":"2026-08-31 23:25","pubTimestamp":1788189904,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics recently reported that The Lancet published peer-reviewed 16-week Phase 2b REZOLVE-AD data showing rezpegaldesleukin improved eczema severity, itch, quality-of-life outcomes, and key biomarkers in adults with moderate-to-severe atopic dermatitis, with all three dosing regimens outperforming placebo.\nThe data, alongside a favorable safety profile and clear T-reg biomarker signal, underpins the ongoing global Phase 3 ZENITH AD program and broad autoimmune ambitions for this...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/peerreviewed-rezolvead-phase-2b-data-could-be-a-game-changer","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/peerreviewed-rezolvead-phase-2b-data-could-be-a-game-changer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013265","title":"Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013265","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013265?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:17","pubTimestamp":1787948275,"startTime":"0","endTime":"0","summary":"BRIEF-Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Aug 28 (Reuters)-Nektar TherapeuticsNKTR.O:NEKTAR THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text:ID:nPn7tb9WqaFurther company coverage:NKTR.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nTUA6VV5W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013408","title":"Nektar Grants Inducement Equity Awards to New Hires, Including Options Priced at USD 74.53","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013408?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:15","pubTimestamp":1787948112,"startTime":"0","endTime":"0","summary":"Nektar grants inducement equity awards to new hires, including options priced at USD 74.53New-hire equity awards granted on Aug. 20, 2026 under Nektar’s 2025 Inducement Plan.Stock options cover 25,200","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL3PHdRN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662340147","title":"Nektar Therapeutics - Rezolve-Ad Study Meets All Primary and Key Secondary Endpoints for Rezpegaldesleukin 24 ΜG/Kg Q2w","url":"https://stock-news.laohu8.com/highlight/detail?id=2662340147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662340147?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:30","pubTimestamp":1787661014,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nFWN44M0S5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661254359","title":"Nektar Therapeutics : JP Morgan Resumes Coverage with Neutral Rating; Target Price $65","url":"https://stock-news.laohu8.com/highlight/detail?id=2661254359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661254359?lang=en_us&edition=fundamental","pubTime":"2026-08-21 12:32","pubTimestamp":1787286745,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I03B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661253664","title":"Nektar Therapeutics’ Earnings Call Highlights Rezpeg Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2661253664","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661253664?lang=en_us&edition=fundamental","pubTime":"2026-08-21 08:15","pubTimestamp":1787271313,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (($NKTR)) has held its Q2 earnings call. Read on for the main highlights of the call. Nektar Therapeutics’ latest earnings call...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-earnings-call-highlights-rezpeg-momentum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-earnings-call-highlights-rezpeg-momentum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660128936","title":"Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660128936","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660128936?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:17","pubTimestamp":1787224632,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics, with a price target of $192.00. Accor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659142286","title":"Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2659142286","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659142286?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:32","pubTimestamp":1786714323,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics has reported past second-quarter 2026 results showing revenue of US$10.13 million and a net loss of US$40.62 million, while also launching global Phase III trials of rezpegaldesleukin in atopic dermatitis and planning Phase III development in alopecia areata, supported by US$1.02 billion in cash and investments with no debt.\nAn interesting angle for investors is that Nektar’s smaller‑than‑expected quarterly loss, extended cash runway into the third quarter of 2028, and...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/is-phase-iii-rezpegaldesleukin-and-cash-runway-progress-alte","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/is-phase-iii-rezpegaldesleukin-and-cash-runway-progress-alte","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NKTR","III","BK4134","PRGS","BK4007","LU2065732104.USD","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659326146","title":"Nektar Therapeutics Falls on Quarterly Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2659326146","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659326146?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:41","pubTimestamp":1786707690,"startTime":"0","endTime":"0","summary":"BUZZ-Nektar Therapeutics falls on quarterly revenue miss** Shares of drug developer Nektar TherapeuticsNKTR.Odown 3.6% at $73.20 premarket** Co reports Q2 rev of $10.1 mln vs. $11.2 mln yr earlier** R","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL4N44B0Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659419876","title":"Nektar Therapeutics Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659419876","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659419876?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:39","pubTimestamp":1786657142,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics reports results for the quarter ended June 30 - Earnings SummaryNektar TherapeuticsNKTR.OQreported a quarterly adjusted loss of $1.23 per share for the quarter ended June 30, highe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A2BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167911","title":"Earnings Flash (NKTR) Nektar Therapeutics Posts Q2 Loss $1.23 Per Share, vs. FactSet Est of $1.97 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167911","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167911?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:24","pubTimestamp":1786652664,"startTime":"0","endTime":"0","summary":"Earnings Flash (NKTR) Nektar Therapeutics Posts Q2 Loss $1.23 Per Share, vs. FactSet Est of $1.97 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659616769","title":"Nektar Q2 FY26 Net Loss Narrows to $40.62 Million; Revenue Falls 9.35% to $10.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659616769","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659616769?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:23","pubTimestamp":1786652622,"startTime":"0","endTime":"0","summary":"Nektar Q2 FY26 net loss narrows to $40.62 million; revenue falls 9.35% to $10.1 millionNektar Therapeutics posted a Q2 net loss of $40.62 million, narrowing from $41.59 million a year earlier.Loss per","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL8DG4PH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659160030","title":"Nektar Q2 2026 Earnings: Phase 3 Spending Rises as Cash and Investments Top $1 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2659160030","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659160030?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:22","pubTimestamp":1786652525,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics’ Q2 2026 revenue fell to $10.1 million from $11.2 million, while net loss narrowed slightly to $40.6 million and loss per share improved to $1.23 from $2.95 as the weighted share count more than doubled. R&D expense rose about 31% to $39.1 million as the company prepared the Phase 3 ZENITH AD program and related manufacturing. Cash and marketable securities reached $1.02 billion, and management said the runway extends into Q3 2028, beyond initial Phase 3 readouts expected in mid-2028.","market":"hk","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock9.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock9.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262103673-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659016783","title":"Nektar Therapeutics Q2 EPS $(1.23) Beats $(2.00) Estimate, Sales $10.131M Miss $10.425M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659016783","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659016783?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:16","pubTimestamp":1786652199,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics Q2 EPS $(1.23) Beats $(2.00) Estimate, Sales $10.131M Miss $10.425M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/NKTR","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nektar Therapeutics Q2 EPS $(1.23) Beats $(2.00) Estimate, Sales $10.131M Miss $10.425M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659316203","title":"Nektar Therapeutics Q2 EPS USD -1.23","url":"https://stock-news.laohu8.com/highlight/detail?id=2659316203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659316203?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:15","pubTimestamp":1786652100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXXMGSX8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157096629","title":"Earning Preview: Nektar Therapeutics revenue expected to decrease by 3.91%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1157096629","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157096629?lang=en_us&edition=fundamental","pubTime":"2026-08-06 12:51","pubTimestamp":1785991876,"startTime":"0","endTime":"0","summary":"Abstract Nektar Therapeutics will release quarterly results on August 13, 2026 (Post-Mkt), with consensus indicating this quarter’s revenue near 10.42 million US dollars, adjusted EPS around -1.99,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Earning Preview: Nektar Therapeutics revenue expected to decrease by 3.91%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655835123","title":"Nektar Therapeutics to Report Q2 Results After U.S. Market Close, Hosts Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2655835123","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655835123?lang=en_us&edition=fundamental","pubTime":"2026-07-29 06:00","pubTimestamp":1785276023,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics to report Q2 results after U.S. market close, hosts conference callNektar Therapeutics schedules Q2 2026 results for Aug. 13, 2026, released post-close.Results conference call set ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL2CSnV6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654471090","title":"Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch?","url":"https://stock-news.laohu8.com/highlight/detail?id=2654471090","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654471090?lang=en_us&edition=fundamental","pubTime":"2026-07-28 02:23","pubTimestamp":1785176602,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) has launched the first two global Phase 3 ZENITH AD trials for rezpegaldesleukin in moderate to severe atopic dermatitis, supported by earlier Phase 2b data and FDA Fast Track designations.\nSee our latest analysis for Nektar Therapeutics.\nThe latest rezpegaldesleukin Phase 3 launch comes after a sharp shift in sentiment around Nektar Therapeutics, with a 1-year total shareholder return of 199.05% and a year to date share price return of 62.89%. However, momentum has...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/is-nektar-therapeutics-nktr-undervalued-on-its-phase-3-rezpe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/is-nektar-therapeutics-nktr-undervalued-on-its-phase-3-rezpe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654030868","title":"Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654030868","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654030868?lang=en_us&edition=fundamental","pubTime":"2026-07-25 05:33","pubTimestamp":1784928802,"startTime":"0","endTime":"0","summary":"BRIEF-Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 24 (Reuters)-Nektar TherapeuticsNKTR.O:NEKTAR THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text:ID:nPn5vrFF1aFurther company coverage:NKTR.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUA99WT6P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654329010","title":"Nektar Grants 36,000 Inducement Stock Options Priced at $64.84 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2654329010","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654329010?lang=en_us&edition=fundamental","pubTime":"2026-07-25 04:15","pubTimestamp":1784924129,"startTime":"0","endTime":"0","summary":"Nektar grants 36,000 inducement stock options priced at $64.84 per shareNektar Therapeutics granted non-qualified stock options covering 36,000 shares to 23 newly hired employees on July 20, 2026.Opti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL2sdshz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.0428},{"period":"1month","weight":0.0153},{"period":"3month","weight":0.2114},{"period":"6month","weight":-0.0097},{"period":"1year","weight":1.4029},{"period":"ytd","weight":0.697}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.01},{"period":"6month","weight":0.1181},{"period":"1year","weight":0.181},{"period":"ytd","weight":0.1171}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.03787},{"month":2,"riseRate":0.53125,"avgChangeRate":0.029488},{"month":3,"riseRate":0.40625,"avgChangeRate":-0.000642},{"month":4,"riseRate":0.46875,"avgChangeRate":0.016904},{"month":5,"riseRate":0.34375,"avgChangeRate":-0.004399},{"month":6,"riseRate":0.424242,"avgChangeRate":0.026471},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.018591},{"month":8,"riseRate":0.484848,"avgChangeRate":0.043831},{"month":9,"riseRate":0.515152,"avgChangeRate":0.041349},{"month":10,"riseRate":0.375,"avgChangeRate":-0.023288},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"Nektar Therapeutics","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nektar Therapeutics,NKTR,Nektar Therapeutics股票,Nektar Therapeutics股票老虎,Nektar Therapeutics股票老虎国际,Nektar Therapeutics行情,Nektar Therapeutics股票行情,Nektar Therapeutics股价,Nektar Therapeutics股市,Nektar Therapeutics股票价格,Nektar Therapeutics股票交易,Nektar Therapeutics股票购买,Nektar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}